| Literature DB >> 30692872 |
Anna Junga1, Māra Pilmane1, Zane Ābola2, Olafs Volrāts2.
Abstract
The regulatory role between ischemia related factors and antimicrobial peptides in congenital intra-abdominal adhesions has not yet been defined. The aim of this research was to investigate the appearance and relative distribution of VEGF, HBD-2, and HGF in congenital intra-abdominal adhesions compared with relatively healthy tissue controls. The study group material was obtained from 48 patients who underwent abdominal surgery due to partial or complete bowel obstruction. VEGF, HBD-2, and HGF were detected using immunohistochemistry methods and their relative distribution was evaluated by means of the semiquantitative counting method. The results were analyzed using nonparametric statistic methods. A moderate number of VEGF positive endotheliocytes were detected, but there was no statistically significant difference between the groups. In the experimental group, a moderate to high number of VEGF positive macrophages was observed. In control group tissues, such macrophages were seen in significantly lower number (U = 61.0, p = 0.001). The increase of VEGF positive cells indicates support of angiogenesis due to the hypoxic conditions in case of adhesion disease. The number of HBD-2 marked fibroblasts and macrophages was moderate to high, but only few positive endotheliocytes were observed. Persisting appearance of HBD-2 positive structures might be a result of the inflammatory process. Most specimens showed occasional HGF positive macrophages and fibroblasts and there was no statistically significant difference between the groups. The relatively weak appearance of HGF suggests that the lack of this factor promotes the formation of fibrotic changes in case of intra-abdominal adhesions.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30692872 PMCID: PMC6332881 DOI: 10.1155/2018/5953095
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Experimental group.
| Age (days)/ Sex | Location | Age (days)/ Sex | Location | Age (days)/ Sex | Location | |||
|---|---|---|---|---|---|---|---|---|
| 1 | 0/M | SI | 17 | 4/F | SI | 33 | 56/M | SI |
| 2 | 0/F | D | 18 | 9/F | D | 34 | 56/F | SI |
| 3 | 0/F | LB | 19 | 9/F | D | 35 | 62/F | D |
| 4 | 1/M | SI | 20 | 9/F | AAW | 36 | 67/M | SI |
| 5 | 1/F | LB | 21 | 9/M | LB | 37 | 71/F | SI |
| 6 | 1/M | SI | 22 | 14/M | SI | 38 | 94/F | SI |
| 7 | 1/F | LB | 23 | 15/M | LB | 39 | 100/F | SI |
| 8 | 1/F | D | 24 | 19/F | SI | 40 | 103/M | D |
| 9 | 1/M | AAW | 25 | 26/F | LB | 41 | 108/M | DI |
| 10 | 2/M | SI | 26 | 28/M | DI | 42 | 129/M | DI |
| 11 | 2/M | SI | 27 | 30/F | SI | 43 | 130/F | D |
| 12 | 2/M | D | 28 | 36/F | SI | 44 | 134/F | SI |
| 13 | 2/M | LB | 29 | 39M | D | 45 | 151/F | SI |
| 14 | 3/M | LB | 30 | 41/F | LB | 46 | 185/F | SI |
| 15 | 4/M | D | 31 | 48/M | LB | 47 | 210/M | DI |
| 16 | 4/F | LB | 32 | 51/F | LB | 48 | 292/F | SI |
Abbreviations: M, male; F, female; SI, small intestine; DI, distal ileum; D, duodenum; LB, Ladd's band; AAW, anterior abdominal wall.
Control group.
| Age (days)/Sex | |
|---|---|
| 1 | 46/F |
| 2 | 53/M |
| 3 | 56/M |
| 4 | 60/F |
| 5 | 73/M |
| 6 | 76/M |
| 7 | 92/M |
| 8 | 145/M |
Abbreviations: M, male; F, female.
Figure 1Immunoreactive structures in congenital adhesions and control group. (a) Moderate VEGF positive endotheliocytes, macrophages, and fibroblasts in congenital adhesions of a 48-day-old patient (VEGF IMH, x250). (b) Moderate VEGF positive endotheliocytes and fibroblasts of a 76-day-old patient in control group (VEGF IMH, x250). (c) Moderate HBD-2 positive fibroblasts, macrophages, and mesotheliocytes in congenital adhesions of a 151-day-old patient (HBD-2 IMH, x250). (d) Moderate HBD-2 positive fibroblasts, macrophages, and endotheliocytes of a 76-day-old patient in control group (HBD-2 IMH, x250). (e) Moderate HGF positive macrophages and epithelioid cells in congenital adhesions of a two-day-old patient (HGF IMH, x250). (f) Few HGF positive mesotheliocytes of a 53-day-old patient in control group (HGF IMH, x250).
Semiquantitative evaluation of immunoreactive structures.
| Experimental grouptb | Control group | U | p | ||
|---|---|---|---|---|---|
| VEGF | Median | ++ | ++ | 124.0 | 0.089 |
| IQR | 0.5 | 0.5 | |||
| HBD-2 | Median | ++/+++ | ++/+++ | 185.5 | 0.951 |
| IQR | 1.5 | 0.5 | |||
| HGF | Median | 0/+ | 0/+ to + | 137.5 | 0.182 |
| IQR | 1.0 | 0.85 |
Abbreviations: VEGF, vascular endothelial growth factor; HBD-2, human beta-defensin-2; HGF, hepatocyte growth factor; IQR, interquartile range; U, Mann Whitney U value. Quantification of structures: 0, no positive structures in the visual field; 0/+, occasionally positive structures in the visual field; +, few positive structures in the visual field; +/++, few to moderate positive structures in the visual field; ++, moderate positive structures in the visual field; ++/+++, moderate to numerous positive structures in the visual field.